Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs02928951
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
D25 | 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole | A,B,C,D | 2VCQ | 0.77 | |
IK8 | 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)- N-(4-{2-[(DIMETHYLAMINO)METHYL]- 1H-IMIDAZOL-1-YL}-2-FLUOROPHENYL)- 3-(TRIFLUOROMETHYL)-1H-PYRAZOLE- 5-CARBOXAMIDE | A | 1Z6E | 0.76 | |
NOW | Nalpha-[(3-tert-butyl-1-methyl- 1H-pyrazol-5-yl)carbonyl]-N-[(2Z)- 2-iminoethyl]-3-methyl-L-phenylalaninamide | A,B,C,D | 3HHA | 0.74 | |
VIA | 5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN- 1-YL)SULFONYL]PHENYL}-1-METHYL- 3-PROPYL-1H,6H,7H-PYRAZOLO[4,3- D]PYRIMIDIN-7-ONE | A | 1XOS | 0.7 | |
VIA | 5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN- 1-YL)SULFONYL]PHENYL}-1-METHYL- 3-PROPYL-1H,6H,7H-PYRAZOLO[4,3- D]PYRIMIDIN-7-ONE | A | 1TBF | 0.7 | |
VIA | 5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN- 1-YL)SULFONYL]PHENYL}-1-METHYL- 3-PROPYL-1H,6H,7H-PYRAZOLO[4,3- D]PYRIMIDIN-7-ONE | A,B,C | 2H42 | 0.7 | |
VIA | 5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN- 1-YL)SULFONYL]PHENYL}-1-METHYL- 3-PROPYL-1H,6H,7H-PYRAZOLO[4,3- D]PYRIMIDIN-7-ONE | A | 1UDT | 0.7 | |
D31 | 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)- N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2- C]PYRAZOL-5-YL)ACETAMIDE | A | 2B55 | 0.7 | |
2E1 | 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)- N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE- 3-CARBOXAMIDE | A | 2CCT | 0.7 | |
LZ9 | {[(2,6-difluorophenyl)carbonyl]amino}- N-(4-fluorophenyl)-1H-pyrazole- 3-carboxamide | A | 2VTP | 0.7 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A | 2HOB | 0.78 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B | 2AMQ | 0.78 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B,C,D | 3D23 | 0.78 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B | 2Q6F | 0.78 | |
GG2 | 1-(4-METHOXYPHENYL)-7-OXO-6-[4- (2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7- TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE- 3-CARBOXAMIDE | A | 2P16 | 0.73 | |
5MR | NALPHA-{(2S)-3-[(S)-HYDROXY(PHENYL)PHOSPHORYL]- 2-[(3-PHENYLISOXAZOL-5-YL)METHYL]PROPANOYL}- L-TRYPTOPHANAMIDE | A,B | 2OVZ | 0.72 | |
5QC | 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)- 6-(2'-{[(3R)-3-HYDROXYPYRROLIDIN- 1-YL]METHYL}BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)- 1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4- C]PYRIDIN-7-ONE | A | 2FZZ | 0.77 | |
LG0 | 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin- 1-ylmethyl)cyclopropyl)phenyl)- 3-(trifluoromethyl)-5,6-dihydro- 1H-pyrazolo[3,4-c]pyridin-7(4H)- one | A | 3CS7 | 0.73 | |
IIA | 1-{[5-(5-CHLORO-2-THIENYL)ISOXAZOL- 3-YL]METHYL}-N-(1-ISOPROPYLPIPERIDIN- 4-YL)-1H-INDOLE-2-CARBOXAMIDE | A,B | 2BOH | 0.71 | |
JK1 | 3-{4-[(phenylcarbamoyl)amino]-1H- pyrazol-1-yl}-N-(3,4,5-trimethoxyphenyl)benzamide | A | 3FI2 | 0.7 | |
AG7 | 4-{2-(4-FLUORO-BENZYL)-6-METHYL- 5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)- AMINO]-4-OXO-HEPTANOYLAMINO}-5- (2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER | A | 1CQQ | 0.78 | |
JNJ | 1-(3-amino-1,2-benzisoxazol-5-yl)- 6-(4-{2-[(dimethylamino)methyl]- 1H-imidazol-1-yl}-2-fluorophenyl)- 7-fluoro-1H-indazole-3-carboxamide | A | 2RA0 | 0.73 | |
19B | 4-methyl-N-(3-morpholin-4-ylphenyl)- 3-(3-piperidin-4-yl-1,2-benzisoxazol- 6-yl)benzamide | A | 3E93 | 0.73 |